Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 10, 2018 - Issue
Submit an article Journal homepage
188
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA

Myrlene S Aigbogun1 Health Economics and Outcomes Research, Otsuka Pharmaceutical Development and Commercialization, Inc, Princeton, NJ, USA, [email protected]Correspondence[email protected]
,
Sizhu Liu2 Global Health Economics and Outcomes Research, Xcenda, Palm Harbor, FL, USA
,
Siddhesh A Kamat1 Health Economics and Outcomes Research, Otsuka Pharmaceutical Development and Commercialization, Inc, Princeton, NJ, USA, [email protected]
,
Christophe Sapin3 Global Analytics, Lundbeck, Paris, France
,
Amy M Duhig2 Global Health Economics and Outcomes Research, Xcenda, Palm Harbor, FL, USA
&
Leslie Citrome4 Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA
Pages 443-456 | Published online: 16 Aug 2018

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Kristen Ward & Leslie Citrome. (2019) Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment 15, pages 247-257.
Read now
Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa & Mondher Toumi. (2019) Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy 7:1.
Read now

Articles from other publishers (10)

Maryam Zabihi Poursaadati, Masoomeh Maarefvand, Jafar Bolhari, Samaneh Hosseinzadeh & Jagdish Khubchandani. (2022) The design and process of a family and community-based intervention for relapse prevention in people living with schizophrenia in Iran. International Journal of Social Psychiatry 69:3, pages 587-601.
Crossref
Shanthi Potla, Yousif Al Qabandi, Savitri Aninditha Nandula, Chinmayi Sree Boddepalli, Sai Dheeraj Gutlapalli, Vamsi Krishna Lavu, Rana Abdelwahab Mohamed Abdelwahab, Ruimin Huang & Pousette Hamid. (2023) A Systematic Review of the Need for Guideline Recommendations; Slow Tapering vs. Maintenance Dose in Long-Term Antipsychotic Treatment: 2022. Cureus.
Crossref
Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters, Ruth A. Duffy, Suresh Mallikaarjun & Craig Bennison. (2021) An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics 40:1, pages 121-131.
Crossref
Luying Wang, Fenghao Shi, Xin Guan, He Xu, Jing Liu & Hongchao Li. (2021) A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia. Frontiers in Public Health 9.
Crossref
A. WERBROUCK, L. ANNEMANS, N. VERHAEGHE & S. SIMOENS. (2021) Gezondheidseconomische evaluaties binnen een preventief beleid: een kritische introductie. Tijdschrift voor Geneeskunde.
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno & Sarah Byford. (2020) A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38:6, pages 537-555.
Crossref
Ilse A. Thompson, Erik F.J. de Vries & Iris E.C. Sommer. (2020) Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment. Current Opinion in Psychiatry 33:3, pages 200-205.
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Christy R. Houle, Heidi C. Waters, Marian H. Tarbox & Michael S. Broder. (2020) Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy. Clinical Therapeutics 42:1, pages 77-93.
Crossref
Zekiye Catak, Hilal Kaya, Esra Kocdemir, Kader Ugur, Saadet Pilten Guzel, Meltem Yardim, Ibrahim Sahin, Esra Piril Agirbas & Suleyman Aydin. (2019) Interaction of apelin, elabela and nitric oxide in schizophrenia patients. Journal of Medical Biochemistry 0:0.
Crossref
. (2018) Brexpiprazole prevents schizophrenia relapse at lower cost. PharmacoEconomics & Outcomes News 810:1, pages 3-3.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.